摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(S)-5-acetylamino-5-(2-methylamino-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl-hydromorphone-di-ester | 1221593-58-3

中文名称
——
中文别名
——
英文名称
[(S)-5-acetylamino-5-(2-methylamino-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl-hydromorphone-di-ester
英文别名
——
[(S)-5-acetylamino-5-(2-methylamino-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl-hydromorphone-di-ester化学式
CAS
1221593-58-3
化学式
C34H49N5O8
mdl
——
分子量
655.792
InChiKey
ZPHKCLHNOUOUPL-AOUIBVPSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    884.8±65.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.67
  • 重原子数:
    47.0
  • 可旋转键数:
    11.0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    155.61
  • 氢给体数:
    3.0
  • 氢受体数:
    9.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS CLIVABLES PAR ENZYME DE PRINCIPES ACTIFS ET LEURS INHIBITEURS
    申请人:PHARMACOFORE INC
    公开号:WO2011133150A1
    公开(公告)日:2011-10-27
    The present disclosure provides pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions comprise a prodrug that provides enzymatically-controlled release of a drug and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the drug from the prodrug so as to attenuate enzymatic cleavage of the prodrug. The disclosure provides pharmaceutical compositions which comprise an enzyme inhibitor and a prodrug that contains an enzyme-cleavable moiety that, when cleaved, facilitates release of the drug.
    本公开提供了一种药物组合物及其使用方法,其中所述药物组合物包含一种前药,该前药能够提供通过酶控释放的药物,以及一种酶抑制剂,该酶抑制剂与介导药物从该前药通过酶控释放的酶相互作用,以减弱前药的酶切。本公开还提供了一种包含酶抑制剂和前药的药物组合物,所述前药包含一个酶可切割的部分,切割后可促进药物的释放。
  • COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF
    申请人:Jenkins Thomas E.
    公开号:US20110262355A1
    公开(公告)日:2011-10-27
    Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an opioid prodrug that provides enzymatically-controlled release of an opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the opioid from the opioid prodrug so as to attenuate enzymatic cleavage of the opioid prodrug.
    提供的药物组合物及其使用方法,其中药物组合物包括一种阿片类药物的前药,该前药提供酶控释放的阿片类药物,以及一种酶抑制剂,该酶抑制剂与介导阿片类药物前药酶控释放的酶相互作用,以减弱对阿片类药物前药的酶切。
  • Pharmaceutical compositions with attenuated release of phenolic opioids
    申请人:Signature Therapeutics, Inc.
    公开号:US09534014B2
    公开(公告)日:2017-01-03
    Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    提供了药物组合物及其使用方法,其中药物组合物包括一种酚类阿片类前药,提供酶控释放酚类阿片类药物,以及一种酶抑制剂,与介导酚类阿片类前药酶控释放的酶相互作用,以减弱前药的酶解。
查看更多